Drug Profile
CCX 872
Alternative Names: CCX 872 B; CCX-872Latest Information Update: 01 Dec 2022
Price :
$50
*
At a glance
- Originator ChemoCentryx
- Class Antifibrotics; Antineoplastics; Hepatoprotectants; Small molecules
- Mechanism of Action CCR1 receptor modulators; CCR2 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Pancreatic cancer
- No development reported Cancer; Focal segmental glomerulosclerosis; Non-alcoholic steatohepatitis
- Discontinued Diabetic nephropathies
Most Recent Events
- 28 Apr 2021 No recent reports of development identified for preclinical development in Cancer in USA
- 28 Feb 2021 No recent reports of development identified for preclinical development in Focal-segmental-glomerulosclerosis in USA (PO)
- 28 Nov 2020 No recent reports of development identified for preclinical development in Non-alcoholic-steatohepatitis in USA (SC)